Bernstein Calls 2026 a “Waiting Year” for Amgen's (AMGN) MariTide [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
On January 20, Bernstein downgraded Amgen Inc. (NASDAQ:AMGN) to Market Perform from Outperform, while leaving its $335 price target unchanged. The firm said the decision was mainly driven by its view that “2026 is a waiting year” for MariTide. Bernstein also flagged a few new issues that could hang over the stock, including possible risk to Repatha as Merck's (MRK) enlicitide pricing comes into focus. The analyst also noted there is still uncertainty around how meaningful Lp(a) outcomes could be, with more clarity expected only after investors can draw comparisons from Novartis' (NVS) pelicarsen data. Separately, on January 6, Amgen said it will acquire Dark Blue Therapeutics Ltd., a privately held biotech company based in the U.K. The transaction is valued at up to $840 million. This deal strengthens Amgen's oncology pipeline by adding an investigational small molecule aimed at degrading two proteins, MLLT1/3, which are believed to drive certain forms of acute myeloid leukemia (
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves [Yahoo! Finance]Yahoo! Finance
- Steve Jobs' son says he can help end cancer deaths - and he's raising millions to do it [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was given a new $400.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.MarketBeat
- AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTSPR Newswire
- Amgen Set to Report Q4 Earnings: What Investors Should Know [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- AMGN's page on the SEC website